Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Idexx Laboratories (IDXX)

Idexx Laboratories (IDXX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 57,057,524
  • Shares Outstanding, K 79,851
  • Annual Sales, $ 3,898 M
  • Annual Income, $ 887,870 K
  • EBIT $ 1,306 M
  • EBITDA $ 1,436 M
  • 60-Month Beta 1.67
  • Price/Sales 13.94
  • Price/Cash Flow 56.87
  • Price/Book 36.15

Options Overview Details

View History
  • Implied Volatility 40.52% (+0.72%)
  • Historical Volatility 20.78%
  • IV Percentile 88%
  • IV Rank 60.94%
  • IV High 52.99% on 04/08/25
  • IV Low 21.07% on 08/12/25
  • Expected Move (DTE 7) 16.40 (2.30%)
  • Put/Call Vol Ratio 1.40
  • Today's Volume 139
  • Volume Avg (30-Day) 162
  • Put/Call OI Ratio 0.81
  • Today's Open Interest 4,208
  • Open Int (30-Day) 4,932
  • Expected Range 695.99 to 728.79

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 2.93
  • Number of Estimates 7
  • High Estimate 3.00
  • Low Estimate 2.87
  • Prior Year 2.62
  • Growth Rate Est. (year over year) +11.83%

Price Performance

See More
Period Period Low Period High Performance
1-Month
661.89 +7.63%
on 01/02/26
724.99 -1.74%
on 01/07/26
+5.74 (+0.81%)
since 12/08/25
3-Month
615.00 +15.84%
on 10/10/25
769.98 -7.48%
on 11/26/25
+82.48 (+13.09%)
since 10/08/25
52-Week
356.14 +100.03%
on 04/09/25
769.98 -7.48%
on 11/26/25
+280.03 (+64.77%)
since 01/08/25

Most Recent Stories

More News
What to Expect From IDEXX Laboratories’ Next Quarterly Earnings Report?

IDEXX Laboratories is expected to release its fiscal fourth-quarter earnings soon, and analysts project a double-digit earnings increase.

XLV : 158.12 (-0.96%)
$SPX : 6,921.46 (+0.01%)
IDXX : 712.39 (-0.30%)
How Is IDEXX Laboratories’ Stock Performance Compared to Other Health Care Stocks?

Although IDEXX Laboratories has outperformed the healthcare sector over the past year, analysts remain cautiously optimistic about the stock’s prospects.

XLV : 158.12 (-0.96%)
ZTS : 126.85 (+0.94%)
IDXX : 712.39 (-0.30%)
Danaher Stock: Is DHR Underperforming the Healthcare Sector?

Despite Danaher’s underperformance relative to the healthcare sector, Wall Street analysts remain strongly optimistic about the stock’s prospects.

XLV : 158.12 (-0.96%)
IDXX : 712.39 (-0.30%)
DHR : 235.00 (-0.24%)
Thermo Fisher Scientific Stock: Is TMO Outperforming the Health Care Sector?

Thermo Fisher Scientific has outperformed the broader healthcare sector over the past year, and analysts continue to hold a strongly bullish view on its growth prospects.

XLV : 158.12 (-0.96%)
TMO : 606.50 (-1.73%)
IDXX : 712.39 (-0.30%)
What Are Wall Street Analysts' Target Price for IDEXX Laboratories Stock?

IDEXX Laboratories has considerably outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s prospects.

XHE : 93.32 (+1.08%)
$SPX : 6,921.46 (+0.01%)
JPM : 329.79 (+0.86%)
IDXX : 712.39 (-0.30%)
Stock Index Futures Plunge on Valuation Concerns

December S&P 500 E-Mini futures (ESZ25) are down -1.01%, and December Nasdaq 100 E-Mini futures (NQZ25) are down -1.31% this morning as quarterly results from AI bellwether Palantir failed to impress investors...

NVDA : 185.04 (-2.15%)
ANET : 123.72 (-4.89%)
SPOT : 553.68 (-2.80%)
SRPT : 23.15 (-1.32%)
GEBN.Z.EB : 638.800 (+0.22%)
MU : 327.02 (-3.69%)
FN : 442.94 (-5.86%)
NQZ25 : 25,132.79s (+0.42%)
AMGN : 330.11 (-3.37%)
PFE : 25.29 (+0.04%)
EDEN.P.DX : 18.855 (+0.11%)
SHOP : 168.28 (+0.92%)
Idexx: Q3 Earnings Snapshot

Idexx: Q3 Earnings Snapshot

IDXX : 712.39 (-0.30%)
IDEXX Laboratories Announces Third Quarter Results

Achieves third quarter revenue growth of 13% as reported and 12% organic, and CAG Diagnostics recurring revenue growth of 11% as reported and 10% organic. ...

IDXX : 712.39 (-0.30%)
What to Expect From IDEXX Laboratories’ Q3 2025 Earnings Report

IDEXX Laboratories is set to announce its third-quarter results next month, with analysts forecasting robust double-digit growth in earnings.

XLV : 158.12 (-0.96%)
$SPX : 6,921.46 (+0.01%)
IDXX : 712.39 (-0.30%)
IDEXX Laboratories to Release 2025 Third Quarter Financial Results

IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2025 third quarter financial results for Monday, November 3, 2025, before...

IDXX : 712.39 (-0.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

IDEXX Laboratories, Inc. is a developer, manufacturer and distributor of products and services primarily for the companion animal veterinary, livestock and poultry, water testing and dairy markets. The company also sells a series of portable electrolytes and blood gas analyzers for the human point-of-care...

See More

Key Turning Points

3rd Resistance Point 738.88
2nd Resistance Point 726.44
1st Resistance Point 719.41
Last Price 712.39
1st Support Level 699.94
2nd Support Level 687.50
3rd Support Level 680.47

See More

52-Week High 769.98
Last Price 712.39
Fibonacci 61.8% 611.89
Fibonacci 50% 563.06
Fibonacci 38.2% 514.23
52-Week Low 356.14

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar